,
, , vol.366
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase, p.367 ,
, Chem. Med. Chem, vol.2, pp.58-61, 2007.
, Patient Resources & Information for IMBRUVICA®, p.7, 2018.
, Development history and FDA approval process for Imbruvica
, Imbruvica -Authorisation details
,
,
Ibrutinib versus 382 temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, p.383 ,
, Lancet, vol.387, pp.770-778, 2016.
,
,
,
, , p.389
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia, N. Engl. J, vol.390 ,
, , vol.371, pp.213-236, 2014.
, , p.393
, , p.394
,
Ibrutinib as initial 396 therapy for patients with chronic lymphocytic leukemia, N. Engl. J. Med, vol.373, pp.2425-2437, 2015. ,
,
,
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia 402 (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial, Lancet Oncol, vol.18, pp.241-250, 2017. ,
,
, , p.407
, Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma, p.408
, Blood, vol.129, pp.2224-2232, 2017.
Natural history of CNS 411 relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 412 8516, J. Clin. Oncol, vol.27, pp.114-119, 2009. ,
Penetration of drugs through the blood-cerebrospinal fluid/blood-415 brain barrier for treatment of central nervous system infections, Clin. Microbiol. Rev, vol.23, pp.858-416, 2010. ,
,
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system 420 relapse, Blood, vol.126, pp.1695-1698, 2015. ,
,
Efficacy of 424 ibrutinib in the treatment of Bing-Neel syndrome, Am. J. Hematol, vol.91, pp.17-19, 2016. ,
Ibrutinib is a safe and 427 effective therapy for systemic mantle cell lymphoma with central nervous system involvement -a 428 multi-centre case series from the United Kingdom, Br. J. Haematol, vol.178, pp.327-329, 2017. ,
Ibrutinib 431 penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome, Br. J, p.432 ,
, , vol.179, pp.339-341, 2017.
Ibrutinib 435 responsive central nervous system involvement in chronic lymphocytic leukemia, Blood, vol.127, pp.436-2356, 2016. ,
,
Efficacy of ibrutinib in a patient with transformed 440 lymphoplasmacytic lymphoma and central nervous system involvement, Leuk. Lymphoma, p.1, 2017. ,
,
Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-445 45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study, J. Pharm. Biomed. Anal, vol.446, pp.151-158, 2015. ,
Liquid 449 chromatography-tandem mass spectrometric assay for the simultaneous determination of the 450 ,
, irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in 451 mouse pharmacokinetic studies, J. Pharm. Biomed. Anal, vol.118, pp.123-131, 2016.
,
Development and Validation of a Simultaneous Quantification Method of 14 ,
, Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS, vol.39, pp.43-54, 2017.
,
Bioanalysis of ibrutinib and its active metabolite in human plasma: 459 selectivity issue, impact assessment and resolution, Bioanalysis, vol.7, pp.2713-2724, 2015. ,
Ultra High Performance Liquid Chromatography Method 462 for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array 463 ,
, Detection, J. Anal. Methods Chem, vol.215128, pp.1-7, 2015.
,
,
, WilsonPhase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated, p.468
, Blood, vol.126, pp.472-472, 2015.
,
Single-Agent Ibrutinib in Recurrent/Refractory Central 472 ,
, Nervous System Lymphoma, Blood, vol.128, pp.783-783, 2016.
,
Harmonization 476 of strategies for the validation of quantitative analytical procedures. A SFSTP proposal -Part I, J, p.477 ,
, Pharm. Biomed. Anal, vol.36, pp.579-586, 2004.
, , p.480
, , p.481
, Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal 482 -part II, J. Pharm. Biomed. Anal, vol.45, pp.70-81, 2007.
,
Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by 486 liquid chromatography coupled to tandem mass spectrometry, J. Pharm. Biomed. Anal, vol.4, pp.487-1139, 2007. ,
Determination of seven selected 490 neuro-and immunomodulatory steroids in human cerebrospinal fluid and plasma using LC-MS/MS, p.491 ,
, Steroids, vol.98, pp.1-8, 2015.
Determination of vandetanib in 494 human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem 495 mass spectrometry (LC-ESI-MS/MS), J. Chromatogr. B, vol.879, pp.2561-2566, 2011. ,
Liquid chromatography/tandem mass 498 spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum 499 and cerebrospinal fluid, J. Pharm. Biomed. Anal, vol.53, pp.576-82, 2010. ,
Quantitative determination of hederagenin in rat 502 plasma and cerebrospinal fluid by ultra fast liquid chromatography-tandem mass spectrometry 503 method, J. Chromatogr. B, vol.879, pp.1973-1979, 2011. ,
A novel liquid chromatography/tandem mass spectrometry 506 method for the quantification of glycine as biomarker in brain microdialysis and cerebrospinal fluid 507 samples within 5min, J. Chromatogr. B, vol.939, pp.92-97, 2013. ,
Bioanalytical method development and validation for the 510 determination of glycine in human cerebrospinal fluid by ion-pair reversed-phase liquid 511 chromatography-tandem mass spectrometry, J. Pharm. Biomed. Anal, vol.128, pp.132-140, 2016. ,
, , p.514
Single-dose pharmacokinetics of ibrutinib in subjects with varying 515 degrees of hepatic impairment, Leuk. Lymphoma, vol.58, pp.185-194, 2017. ,
, , p.518
Absorption, metabolism, and excretion of oral 14 C radiolabeled 519 ibrutinib: an open-label, phase I, single-dose study in healthy men, Drug Metab. Dispos, vol.43, p.520, 2015. ,